Drugs / HEC93077
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05127772 | Nov 2021 → Oct 2023 | gout | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC93077 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05127772 ↗ |
| Route | Oral | “Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days” NCT05127772 ↗ |